Duraibabu Prathyusha 4

What Happened
Duraibabu Prathyusha, Principal Financial Officer of Sangamo Therapeutics (SGMO), had 36,676 shares surrendered to the company on January 22, 2026 to satisfy mandatory tax withholding related to vested restricted stock units (RSUs). The filing reports the disposition at $0.40/share for a total of $14,615 (issuer closing price used was $0.3985/share). This was a tax-withholding disposition (transaction code F), not an open-market sale or discretionary trade.

Key Details

• Transaction date: January 22, 2026; reported filing date: January 26, 2026 (timely within the 2-business-day Form 4 window).
• Reported price/value: 36,676 shares at $0.40/share = $14,615 (issuer closing price $0.3985/share used for withholding).
• Transaction code: F (shares surrendered for tax withholding).
• Shares owned after transaction: Not stated in the Form 4 provided.
• Footnote F1: Surrender was solely for mandatory tax withholding under the Issuer’s equity plan and is treated as a disposition for reporting—this was not a discretionary open-market sale.
• Footnote F2: Describes remaining RSU vesting schedule (includes 52,387 shares vested on Jan 22, 2026, plus other future vesting tranches from 2023 and 2025 grants) and notes vesting is subject to continued service and potential acceleration per the plan.

Context: This is a routine administrative tax-withholding transaction tied to RSU vesting. Such surrendering of shares to cover taxes is common and does not, by itself, indicate the insider’s view on the company.